Research Article

LL-37: The Human Body's Natural Antimicrobial Peptide

LL-37 is the only human cathelicidin—a natural antimicrobial peptide that serves as our first line of defense against pathogens. We explore the research on this immune system workhorse.

Antimicrobial Peptides12 min readNovember 8, 2025

Introduction

While many peptides in research are synthetic or derived from other species, LL-37 is authentically human. It's the only cathelicidin antimicrobial peptide produced by the human body, serving as a critical component of our innate immune defense.

What Is LL-37?

LL-37 is a 37-amino acid peptide derived from the C-terminus of the human cathelicidin protein (hCAP18). The name comes from its two N-terminal leucine residues (LL) and its length (37 amino acids).

Where It's Found

  • Skin epithelial cells
  • Respiratory tract lining
  • Gastrointestinal mucosa
  • Immune cells (neutrophils, macrophages)
  • Body fluids (sweat, saliva, breast milk)

Mechanisms of Action

LL-37 is a multifunctional peptide with several distinct activities:

1. Direct Antimicrobial Action

  • Bacteria: Disrupts bacterial membranes, causing cell death
  • Viruses: Can neutralize enveloped viruses
  • Fungi: Active against various fungal species
  • Parasites: Some antiparasitic activity demonstrated

2. Immunomodulation

LL-37 doesn't just kill pathogens—it orchestrates the immune response:

  • Attracts immune cells to infection sites (chemotaxis)
  • Modulates dendritic cell activation
  • Influences T-cell responses
  • Can both promote and suppress inflammation depending on context

3. Wound Healing

  • Promotes keratinocyte migration
  • Stimulates angiogenesis (new blood vessel formation)
  • Enhances tissue repair

4. Anti-Biofilm Activity

Biofilms are notoriously difficult to treat. LL-37 can:

  • Prevent biofilm formation
  • Disrupt established biofilms
  • Enhance antibiotic penetration into biofilms

The Vitamin D Connection

One of the most clinically relevant aspects of LL-37 is its regulation by vitamin D. Vitamin D directly upregulates LL-37 expression, which may explain some of vitamin D's immune benefits.

This connection suggests that:

  • Vitamin D deficiency may impair innate immunity partly through reduced LL-37
  • Vitamin D supplementation could boost antimicrobial peptide levels
  • Seasonal variations in vitamin D might affect infection susceptibility

Research Applications

Infectious Disease

LL-37 is being studied for:

  • Antibiotic-resistant bacterial infections
  • Wound infections
  • Respiratory infections
  • Sepsis

Autoimmune Conditions

Interestingly, LL-37 is implicated in some autoimmune diseases:

  • Psoriasis: Elevated LL-37 may trigger autoimmune responses
  • Lupus: LL-37-DNA complexes can activate immune cells
  • Rosacea: Abnormal LL-37 processing contributes to inflammation

This dual nature—protective against infection but potentially harmful in autoimmunity—highlights the complexity of immune peptides.

Cancer Research

Early research suggests LL-37 may have anticancer properties:

  • Direct cytotoxicity to some cancer cells
  • Immunomodulation that could enhance antitumor responses
  • However, some studies show it may promote tumor growth in certain contexts

Synthetic Analogs and Fragments

Researchers are developing modified versions of LL-37 to improve therapeutic potential:

LL-37 Fragments

  • Shorter peptides derived from LL-37
  • May retain antimicrobial activity with improved safety
  • Easier and cheaper to synthesize

Modified Analogs

  • Enhanced stability
  • Reduced toxicity to human cells
  • Improved activity spectrum

Challenges in Therapeutic Development

Stability Issues

Like many peptides, LL-37 is susceptible to degradation by proteases, limiting its use as a systemic therapeutic.

Dual-Edged Sword

LL-37's role in autoimmune diseases means therapeutic applications must be carefully considered—boosting LL-37 could potentially trigger or worsen autoimmune conditions in susceptible individuals.

Production Costs

The 37-amino acid length makes LL-37 relatively expensive to synthesize at pharmaceutical scale.

Current Research Status

LL-37 is not approved as a therapeutic agent anywhere in the world. It remains in the research phase, with studies focusing on:

  • Topical applications for wound healing
  • Inhaled formulations for respiratory infections
  • Synthetic analogs with improved properties

Natural Ways to Support LL-37 Production

While synthetic LL-37 isn't available therapeutically, you can support your body's natural production:

  1. Maintain adequate vitamin D levels: Direct upregulation of LL-37
  2. Butyrate (from fiber): May increase LL-37 expression in the gut
  3. Avoid excessive inflammation: Chronic inflammation can dysregulate LL-37
  4. Support gut health: The microbiome influences antimicrobial peptide production

Conclusion

LL-37 represents one of evolution's elegant solutions to pathogen defense—a single peptide that can kill microbes, recruit immune cells, regulate inflammation, and promote healing. While therapeutic applications remain in development, understanding this peptide illuminates how our bodies naturally fight infection.


This article is for educational purposes only. LL-37 is not approved for therapeutic use.

Related Peptides

DMR

Dr. Michael Roberts

MD, PhDResearching Peptides Medical Advisor

Dr. Roberts provides medical oversight and ensures content accuracy for clinical research topics. With over 15 years of experience in endocrinology research, he brings valuable expertise to our editorial process.